COPENHAGEN, Denmark & HORSHAM, Pa.--(BUSINESS WIRE)--Novo Nordisk A/S (NYSE:NVO) and Neose Technologies, Inc. (NasdaqGM:NTEC) today announced that Novo Nordisk has initiated a Phase I clinical trial of GlycoPEGylated Factor VIIa, a long-acting version of NovoSeven® Coagulation Factor VIIa (Recombinant). The trial will assess the safety and pharmacokinetics of GlycoPEGylated Factor VIIa in healthy volunteers. GlycoPEGylated Factor VIIa is being developed by Novo Nordisk under a license agreement with Neose. The initiation of the Phase I study triggers an undisclosed milestone payment to Neose under the license agreement.
